Researchers used AI models to design antibodies that neutralize over 1,300 SARS-CoV-2 strains, including Delta and Omicron.

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster ...